GHSI Score Converter

Convert GHSI, GHSI-AO, and PGSI scores to harm categories, ICECAP-A and SF-6D tariffs.

This tool converts scores from different versions of the Gambling Harms Severity Index (GHSI-3, GHSI-7, or GHSI-10) into a GHSI harm category and estimated health utility tariffs on the ICECAP-A and SF-6D scales. The Affected Others tab provides the same conversions for the Affected Others (GHSI-AO-3, GHSI-AO-7, or GHSI-AO-10) versions. You can also convert PGSI (Problem Gambling Severity Index) scores to GHSI-10 equivalents using the Alternative Measures tab. If you enter a shorter-form or alternative measure score, it will first be converted to a GHSI-10 (or GHSI-AO-10) equivalent.

Valid range: 0 – 21

Valid range: 0 – 21

Valid range: 0 – 27

GHSI Harm Category

ICECAP-A Tariff

Disutility:

SF-6D Tariff

Disutility:

Understanding Health Utility and Disutility

The ICECAP-A and SF-6D scores shown above are measures of health utility. Health utility is a standard approach in health economics and is routinely used by NICE and the NHS to assess whether interventions are clinically meaningful and represent good value for money.

Health utility is a way of measuring quality of life on a scale from 0 to 1. A score of 1 represents full health and wellbeing, while 0 represents a state considered equivalent to death. In UK population studies, average scores are typically around 0.86 on the ICECAP-A and 0.90 on the SF6D (see research publications).

These measures allow gambling harms to be understood in the same way as other long-term conditions, enabling direct comparison with mental health disorders, addictions, and chronic illness.

We use two complementary measures because gambling harms affect people in different ways:

Disutility refers to the reduction in wellbeing compared to a healthy population. As GHSI (or GHSI-AO) scores increase (indicating greater harm), health utility scores decrease.

In practical terms, a 2–3 point change on the GHSI corresponds to changes in quality of life that meet accepted thresholds for clinical meaningfulness in NICE-aligned health-economic evaluation.”